Who are MPSV4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MCV4, MenACWY, MenACYW135 polysaccharide vaccine, Meningococcal ACWY Conjugate Vaccine, MenACWY, MenitorixTM, MenACWY-TT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mpsv4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MPSV4 — Competitive Intelligence Brief

MPSV4 (MPSV4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Meningococcal conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Meningococcal conjugate vaccine Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MPSV4 (MPSV4) — CanSino Biologics Inc.. MPSV4 is a meningococcal polysaccharide conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MPSV4 TARGET	MPSV4	CanSino Biologics Inc.	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MCV4	MCV4	CanSino Biologics Inc.	marketed	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenACWY	MenACWY	LimmaTech Biologics AG	marketed	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenACYW135 polysaccharide vaccine	MenACYW135 polysaccharide vaccine	Sanofi	phase 3	Conjugate polysaccharide vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
Meningococcal ACWY Conjugate Vaccine, MenACWY	Meningococcal ACWY Conjugate Vaccine, MenACWY	GlaxoSmithKline	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenitorixTM	MenitorixTM	GlaxoSmithKline	phase 3	Meningococcal conjugate vaccine	Neisseria meningitidis serogroups A, C, W, Y polysaccharide capsules
MenACWY-TT	MenACWY-TT	Pfizer	marketed	Meningococcal conjugate vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Meningococcal conjugate vaccine class)

GlaxoSmithKline · 8 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 2 drugs in this class
Novartis · 1 drug in this class
Pfizer · 1 drug in this class
University of British Columbia · 1 drug in this class
International Vaccine Institute · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MPSV4 — Competitive Intelligence Brief. https://druglandscape.com/ci/mpsv4. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab